ACA
ACAD icon

Avoro Capital Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Avoro Capital Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,275,000
Closed -$55.1M – 41
2022
Q1 		$55.1M Buy
2,275,000
+75,000
+3% +$1.81M 1.01% 19
2021
Q4 		$51.3M Hold
2,200,000
– – 0.87% 19
2021
Q3 		$36.5M Sell
2,200,000
-241,658
-10% -$4.66M 0.57% 27
2021
Q2 		$59.6M Sell
2,441,658
-58,342
-2% -$1.32M 1.04% 22
2021
Q1 		$64.5M Buy
2,500,000
+550,000
+28% +$24.2M 1.11% 20
2020
Q4 		$104M Buy
+1,950,000
New +$96.8M 1.8% 16
2020
Q2 		– Sell
-145,000
Closed -$6.13M – 46
2020
Q1 		$6.13M Buy
+145,000
New +$5.97M 0.21% 40
2019
Q4 		– Sell
-887,500
Closed -$31.9M – 32
2019
Q3 		$31.9M Sell
887,500
-437,500
-33% -$13.3M 1.33% 18
2019
Q2 		$35.4M Hold
1,325,000
– – 1.22% 19
2019
Q1 		$35.6M Buy
+1,325,000
New +$30.9M 1.54% 19
2018
Q4 		– Sell
-100,000
Closed -$2.08M – 36
2018
Q3 		$2.08M Buy
+100,000
New +$1.57M 0.1% 39
2018
Q2 		– Sell
-317,100
Closed -$7.13M – 44
2018
Q1 		$7.13M Buy
+317,100
New +$8.78M 0.34% 36
2017
Q3 		– Sell
-614,200
Closed -$17.1M – 44
2017
Q2 		$17.1M Sell
614,200
-1,015,800
-62% -$30.3M 2.16% 14
2017
Q1 		$56M Buy
1,630,000
+143,540
+10% +$5.07M 7.16% 4
2016
Q4 		$42.9M Buy
1,486,460
+693,961
+88% +$18.4M 8.66% 1
2016
Q3 		$25.2M Buy
792,499
+462,999
+141% +$15.7M 4.42% 8
2016
Q2 		$10.7M Buy
+329,500
New +$11M 2.38% 15
2015
Q4 		– Sell
-581,900
Closed -$19.2M – 30
2015
Q3 		$19.2M Buy
581,900
+86,900
+18% +$3.62M 5% 6
2015
Q2 		$20.7M Buy
+495,000
New +$19.2M 5.71% 6

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Avoro Capital Advisors's ACAD Position: Q2 2022 in Review

Avoro Capital Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q2 2022, closing a stake of 2,275,000 shares — an estimated $55.1M sold.

Avoro Capital Advisors first reported a position in ACAD in Q2 2015 and held it in 19 quarters. The position peaked at $104M in Q4 2020. 246 funds tracked by Wall St. Rank hold ACAD as of Q2 2022.

  • Avoro Capital Advisors reported no remaining Acadia Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Avoro Capital Advisors sold 2,275,000 Acadia Pharmaceuticals shares in Q2 2022, an estimated $55.1M.
  • Avoro Capital Advisors first reported a position in Acadia Pharmaceuticals in Q2 2015 and held it in 19 quarters.
  • Avoro Capital Advisors's Acadia Pharmaceuticals position peaked at $104M in Q4 2020.
  • 246 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2022.

Based on Avoro Capital Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.